Drug Profile


Alternative Names: Akynzeo; NEPA; NEPA - Helsinn; Netupitant-palonosetron fixed dose combination (NEPA); Palonosetron/netupitant

Latest Information Update: 31 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Helsinn
  • Developer Helsinn; Taiho Pharmaceutical; Vifor Pharma
  • Class Antiemetics; Isoquinolines; Pyridines; Quinuclidines; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; Neurokinin 1 antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 31 Jul 2017 Chemical structure information added
  • 06 Jun 2017 Helsinn completes a phase III trial in Chemotherapy induced nausea and vomiting (Prevention) in South Korea (PO) prior to June 2017
  • 02 Jun 2017 Efficacy and adverse events data from a phase III trial in Chemotherapy induced nausea and vomiting presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top